Improving Recovery and Outcomes Every Day after the ICU (IMPROVE): study protocol for a randomized controlled trial
Delirium affects nearly 70% of older adults hospitalized in the intensive care unit (ICU), and many of those will be left with persistent cognitive impairment or dementia. There are no effective and scalable recovery models to remediate ICU-acquired cognitive impairment and its attendant elevated risk for dementia or Alzheimer disease (AD). The Improving Recovery and Outcomes Every Day after the ICU (IMPROVE) trial is an ongoing clinical trial which evaluates the efficacy of a combined physical exercise and cognitive training on cognitive function among ICU survivors 50 years and older who experienced delirium during an ICU stay. This article describes the study protocol for IMPROVE.
IMPROVE is a four-arm, randomized controlled trial. Subjects will be randomized to one of four arms: cognitive training and physical exercise; cognitive control and physical exercise; cognitive training and physical exercise control; and cognitive control and physical exercise control. Facilitators administer the physical exercise and exercise control interventions in individual and small group formats by using Internet-enabled videoconference. Cognitive training and control interventions are also facilitator led using Posit Science, Inc. online modules delivered in individual and small group format directly into the participants’ homes. Subjects complete cognitive assessment, mood questionnaires, physical performance batteries, and quality of life scales at baseline, 3, and 6 months. Blood samples will also be taken at baseline and 3 months to measure pro-inflammatory cytokines and acute-phase reactants; neurotrophic factors; and markers of glial dysfunction and astrocyte activation.
This study is the first clinical trial to examine the efficacy of combined physical and cognitive exercise on cognitive function in older ICU survivors with delirium. The results will provide information about potential synergistic effects of a combined intervention on a range of outcomes and mechanisms of action.
ClinicalTrials.gov, NCT03095417. Registered on 23 March 2017. Last updated on 15 May 2017.
KeywordsDelirium Physical exercise Cognitive training Critical care Biomarkers Alzheimer disease Dementia Aging Post-intensive care syndrome Internet delivery Physical activity Cognitive impairment
Advanced Cognitive Training for Independent and Vital Elderly
Analysis of covariance
Brain-derived neurotrophic factor
Confusion Assessment Method for the ICU
Chronic obstructive pulmonary disease
Drug Abuse Screening Test
Generalized Anxiety Disorder Scale
Glial fibrillary acidic protein
Intensive care unit
Insulin growth factor-1
Improving Recovery and Outcomes Every Day after the ICU
Mental Component Summary
Physical Component Summary
Patient Health Questionnaire-9
Repeatable Assessment of Neuropsychological Status
Rating of perceived exertion
36-Item Short Form Health Survey
Short Physical Performance Battery
Tumor necrosis factor
Vascular endothelial growth factor
Delirium is defined as acute brain dysfunction characterized by an inability to focus, sustain, or shift attention that develops quickly and tends to fluctuate throughout the day . Nearly 70% of older adults who become critically ill and require hospitalization in the intensive care unit (ICU) develop delirium. ICU delirium can lead to immediate in-hospital complications including a longer length of ICU and hospital stay, increased risk of in-patient mortality, and elevated costs of care. In addition, ICU delirium is associated with long-term post-discharge complications, such as the development of cognitive impairment and dementia [2, 3, 4, 5].
Physical activity has been found to enhance angiogenesis, neurogenesis, the release of neurotrophic factors, and neuroplasticity in animal studies [9, 10, 11]. Exercise has also been found to increase cerebral blood flow, oxygen extraction and glucose use, and reduce inflammation [12, 13]. Older patients who perform aerobic exercise showed the greatest increase in blood volume in frontal and parietal lobe white matter [14, 15, 16, 17, 18]. Executive cognitive ability showed the largest response to exercise as compared to other cognitive domains. Gains were also greater for training that lasted 30–45 min (versus longer or shorter) and older subjects (versus ones that were age 55–65) [19, 20, 21, 22, 23, 24, 25]. Physical activity also improves cognition in well older adults, and those with mild cognitive impairment, AD, stroke, chronic obstructive pulmonary disease (COPD), and traumatic brain injury [19, 20, 21, 22, 23, 24, 25].
Cognitive training has also been demonstrated to have favorable cognitive effects. The largest and most rigorous investigation of the efficacy of cognitive training is the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) trial. ACTIVE randomized 2802 well-functioning, community-dwelling adults (65 years and older) to Memory, Reasoning, Speed of Processing training, or a no-contact control group . Each ACTIVE intervention produced an immediate improvement in the trained ability with largest improvements observed for the Speed of Processing intervention followed by Reasoning and Memory. Treatment effects were maintained for 5 years on Memory, Reasoning, and Speed trained participants relative to controls and up to 10 years for Reasoning and Speed. A recent meta-analysis of trials of cognitive training on persons with MCI also found mild to moderate cognitive benefits from cognitive training although the long-term effects are not clear .
The biochemical pathways through which physical and cognitive exercise can improve cognition are still being characterized. Physical exercise appears to mitigate endothelial dysfunction and vascular wall inflammation, and enhances neural substrates brain-derived neurotrophic factor (BDNF) and insulin growth factor-1 (IGF-1) that maximize the effects of subsequent cognitive stimulation [28, 29]. Similarly, cognitive therapy may exert its favorable effect by increasing levels of BDNF. This was shown in a randomized trial of 8 weeks of cognitive therapy versus health education among patients with heart failure . Patients randomized into the cognitive therapy arm showed an increase in their BDNF levels at 8 weeks compared to baseline levels as well as improvement in working memory, whereas the BDNF levels decreased in the education control.
Based on the above findings, we hypothesize that combined physical exercise and cognitive training will produce improved biologic and physiologic substrates with increased BDNF and IGF-1 leading to neural proliferation and improved inflammatory environment [decrease in tumor necrosis factor (TNF)-α, interleukin (IL)-1, 6, 8, and C-reactive protein (CRP)]. These changes in turn will promote improvements to brain structure (increased frontal and temporal gray matter density) and neural activation, and reduce astrocyte and microglial activation [decrease in S-100β and glial fibrillary acidic protein (GFAP)].
The primary outcome of IMPROVE is to determine the effects of the combined physical exercise and cognitive training on the cognitive function of ICU survivors aged 50 and older. The secondary outcomes of IMPROVE are to determine the effects of the combined physical exercise and cognitive training on physical performance, anxiety and depressive symptoms, and quality of life of this patient population, and to examine the mechanisms of action of combined training by measuring biomarkers relevant to delirium and dementia [6, 31, 32].
Study setting and design
The target population for the IMPROVE trial is adults aged 50 and older who have survived a critical illness in the ICU and had a delirium episode during their ICU stay at any of the three Indiana University School of Medicine-affiliated hospitals; IU Health (IUH) Methodist Hospital; IUH University Hospital; and Eskenazi Hospital. Trained research assistants will screen eligible individuals (those who meet inclusion criteria and do not meet any exclusion criteria) who will be screened twice per day for delirium until ICU discharge using the Confusion Assessment Method for the ICU (CAM-ICU) . Patients who screened positive on the CAM-ICU and survived the ICU stay will be approached for enrollment into the study within 48 h of their anticipated hospital discharge.
Outcomes assessments will be conducted by research assistants who are blinded to randomization assignment at 3 and 6 months post baseline. Outcomes assessments consist of measures of cognition, physical function, depression and anxiety, and quality of life (see Outcome measures section in Fig. 4). Data will be collected and stored using Research Electronic Data Capture (REDCap). Research assistants will undergo training and certification procedures with a supervisor for quality assurance. Ongoing quality assurance checks are performed by the supervisor at regular intervals. Subjects will be instructed not to discuss their assigned intervention with the research assistants.
Age ≥ 50 years
Admitted to medical or surgical ICU at Methodist, University, or Eskenazi hospitals
Discharged home or subacute rehabilitation
Able to provide consent or has a legally authorized representative to provide consent
Access to a telephone
Have at least one episode of delirium as determined by the Confusion Assessment Method in the ICU
Diagnosis of cancer with short life expectancy
Current chemotherapy or radiation therapy
History of dementing illnesses and other neurodegenerative diseases such as Alzheimer disease, Parkinson disease, or vascular dementia
Current alcohol consumption ≥ 5 drinks per day
Vision < 20/80 via Snellen card
Low hearing or communicative ability (examiner rated) that would interfere with interventions and outcome assessments
Presence of delirium at time of hospital discharge
Presence of American College of Sports Medicine absolute or relative contraindications to exercise
Recovering from a skeletal fracture
Stroke as the admitting diagnosis or a new event during the course of hospitalization
Recent history of drug abuse [Drug Abuse Screening Test (DAST-20) score > 5]
Enrolled subjects randomized to the active cognitive intervention will receive facilitator-led cognitive training via computer-accessed online training modules 45 min per session, 2 days per week for 3 months; and physical exercise delivered by trained facilitators to participants in their homes via Internet-based single or multi-party (2–6 per group) videoconference 45 min per session, three times per week for 3 months.
The active cognitive intervention consists of several modules from Brain HQ developed by Posit Science, Inc., that engage time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, dual task, and memory. Exercises adapt to participants’ level of performance and automatically advance in difficulty level as performance improves.
The cognitive control intervention consists of control modules also from Brain HQ. The cognitive control activities happen at the same frequency as the active cognitive intervention.
The active physical exercise intervention consists of 45 min of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. Three sessions per week for 3 months will be delivered. Participant’s heart rate and rating of perceived exertion (RPE) will be used to ascertain achievement of moderate intensity exercise. Participants will be advised to exercise at the RPE level of 5–6 on a 10-point scale, equating to moderate-intensity exercise for adults over the age of 40 years. Each physical exercise session will be divided as follows: 5 min of warm-up, 10 min of upper-body, 10 min of core, 10 min lower-body, 5 min of upper-body and lower-body, and 5 min of cool-down and flexibility exercises. All exercises will be conducted from a seated position in a solid backed chair.
The physical exercise control will consist of gentle, seated stretching. Three sessions per week for 3 months will be delivered.
The primary outcome will be cognitive performance at 3 and 6 months. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total index score will provide the primary outcome for the trial . Secondary outcomes will be assessed using individual tests of processing speed, executive control, and new learning ability as follows: Trail Making Test Part A and B (seconds to complete), and Stroop Color and Word Test (interference trial). These measures sample major domains of cognition affected in ICU survivors.
Secondary outcomes will also include mood symptoms, physical performance, quality of life, and biomarkers relevant to delirium and dementia. All secondary outcomes, except for biomarkers, will be measured at 3 and 6 months. Mood symptoms will be assessed with Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Scale-7 (GAD-7) to determine the impact of the intervention on the ICU’s survivors’ mood and anxiety. The PHQ-9 is a nine-item depression scale with a total score from 0 to 27 [35, 36] and the GAD-7 is a seven-item anxiety scale with a total score from 0 to 21 [37, 38].
Physical training effects on balance and strength will be assessed via the Short Physical Performance Battery (SPPB), a validated objective assessment [39, 40]. The SPPB yields a performance score of 0–12 (0–4 poor, 5–7 intermediate, 8–12 good). A difference of 1 point indicates a significant change in function. Physical training effects on cardiovascular fitness will be assessed via the 2-min step test and grip strength. The 2-min step test for cardiovascular fitness is a validated measure of aerobic capacity, does not require equipment, and can be used in the home setting. Grip strength will be measured using a JAMAR hand dynamometer .
The Medical Outcome Study Short Form (SF-36) will be used to measure quality of life. It has eight components (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) that are aggregated into a Physical Component Summary (PCS) and a Mental Component Summary (MCS). The PCS and the MCS will be used as quality of life outcomes.
Biomarkers will be measured at baseline and 3 months: pro-inflammatory cytokines (IL-1, 6, 8, TNF-α); the acute-phase reactant (CRP); neurotrophic factors [IGF-1, vascular endothelial growth factor (VEGF), BDNF]; markers of glial dysfunction and astrocyte activation (S-100β, GFAP); and AD-related biomarkers (APOE genotype, plasma amyloid-β Aβ42/Aβ40) [31, 32].
Statistical analyses will be conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). Differences in patients’ baseline characteristics among the four groups will be compared using analysis of covariance (ANCOVA) for continuous variables and the Cochran-Mantel-Hansel statistic for categorical variables while adjusting for stratification variables.
Mixed effects models will be used with repeated RBANS scores collected at baseline, 3 months, and 6 months as the outcome measures, group, time, and a group by time interaction as independent variables while adjusting for stratification variables and other potential baseline covariates found to be significantly different in univariate comparisons. A significant interaction between group and time would indicate differences in changes of cognitive functions over time among the four groups. Post hoc comparisons will be conducted following a significant interaction between group and time to compare the effect of the combined training group to the other three groups (attention control, cognitive training only, and exercise only groups) at 3 month for immediate training effect and at 6 months for sustained training effect. Separate mixed-effect models will also be used for repeated Trail Making Test Part A and B and Stroop Color and Word Test.
Similarly, separate mixed-effects models will be used with repeated measures (SPPB, 2-min step, PHQ-9, GAD-7, SF-36 PCS and MCS) as the outcome variables, group, time, and interactions between group and time as independent variables, while adjusting for stratification variables and other baseline covariates that may be different among the four groups. Significant interactions between group and time in these models would indicate differences in changes of functional outcomes, depressive symptoms, and anxiety levels or quality of life over time among the four groups. Post hoc analyses will also be conducted following significant interactions in the mixed-effects models to compare the combined training group to the other three groups and to determine how early a group difference can be detected and whether the effect extends beyond the training period.
Changes in the serum levels of CRP, IL-1, IL-6, IL-8, TNF-α, S-100β, GFAP, BDNF, VEGF, and IGF-1, and plasma levels of amyloid beta Aβ42/Aβ40 will be calculated and used as the dependent variables in ANCOVA models with group as the independent variable and adjusting for stratification variables and baseline covariates that are found to be different among the groups in univariate comparisons. Post hoc comparisons will be used following a significant group effect to compare biomarker levels in the combined training group to the other three groups.
Missing data are expected due to patient death (mostly within 30 days of ICU discharge) and withdrawal from treatment. Patient death rates are expected to be equal across all four groups. The mixed-effects model approach is robust under the missing at random assumption, i.e. the probability of missing is unrelated to the missing observations. Baseline characteristics of subjects with missing outcomes due to death or dropout during follow-up will be compared to detect potential violation to the missing at random assumption. Intention to treat analysis will be used in all models. Further sensitivity analyses will be performed using various methods of imputation or a full parametric likelihood approach assuming various patterns of missing data .
Sample size calculation was performed as follows. For the primary outcome to measure differences in cognitive effects, cognitive training has been found to have a moderate effect size of approximately 0.5 SD and the combined training was found to have a larger effect size of 0.9 SD when comparing to the control group in healthy elderly subjects [43, 44, 45]. Assuming effect sizes of 0.4 SD in the cognitive training only group and the exercise-only groups at 3 and 6 months post baseline compared to the attention control group and effect size of 0.8 SD in the combined training group at 3 and 6 months post baseline compared to the control group, a sample size of 60 patients in each group will yield 83% power at detecting a significant group by time interaction in a mixed-effects model adjusting for correlations of 0.2 for outcomes measured 3 months apart, and correlations of 0.1 for outcomes measured 6 months apart at α = 0.05. The power estimation was conducted using the GLMPower procedure in SAS. To further assume that 30% patients may miss some post-baseline assessments, we will need to enroll a total of 344 patients into the study (86 patients per group).
The proposed analyses for the outcomes for the mood questionnaires, physical performance battery, and quality of life scales will also have 83% power to detect effect sizes similar to those described for the primary outcome about cognitive effects. For the proposed analyses in changes in biomarkers, there will be 81.7% power to detect an overall treatment effect with effect sizes of 0.31 SD in the cognitive training only and the exercise only groups and 0.62 SD in the combined training groups at α = 0.05 using one-way ANOVA and the Power procedure in SAS.
The exercise program elements will include warm-up, flexibility exercise, moderate intensity exercise, and a gradual progression of exercise intensity and duration, and cool down. These elements are associated with lower risks of cardiovascular complications and muscular injury. The Interventionist will educate subjects about the signs and symptoms of angina, myocardial infarction, and muscle/tendon-related injuries and how to respond to them; a procedure recommended by the American College of Sports Medicine and the American Heart Association as effective means of reducing complications to exercise [46, 47]. The Data and Safety Monitoring Plan includes the identification and response to serious cardiac events and orthopedic injuries in the Protection of Human Subjects section. Interventionists will be alert to signs of anxiety and frustration displayed by subjects during cognitive training. Interventionists will monitor reactions closely and respond appropriately with encouragement and suggestions to reduce burden.
Despite the high prevalence of post-ICU cognitive impairment and dementia, there are no effective and scalable recovery models to remediate these complications. IMPROVE represents a major step forward in the field of post-ICU cognitive impairment by proposing a novel home-based combined physical exercise and cognitive training program. The approach to deliver these trainings through the Internet increases the feasibility of participation and has the potential for widespread dissemination of this modality. The design of IMPROVE is based on a combination of previous knowledge about the effect of cognitive and physical training on cognitive outcomes and older adults, and the underlying pathophysiology of long-term cognitive impairment due to ICU delirium.
There are, however, limitations related to the sample. Previous studies suggest the majority of deaths and hospital readmission occur within the first 30 days of ICU discharge [48, 49]. More than 15% of ICU patients are hospitalized within 30 days of discharge . Likewise, the 30-day mortality rate for adult ICU patients is also higher than 15% . Exclusion criteria have been designed to increase the likelihood of selecting participants with at least a 6-month life expectancy. Assistive devices (glasses, headphones or pocket talker) will also be provided during interventions and assessments when indicated.
Despite these limitations, IMPROVE is innovative in several aspects. First, this is the first clinical trial in ICU survivors of delirium to examine the efficacy of interventions in isolation (physical exercise versus cognitive training versus attention control) or in combination (physical exercise plus cognitive training versus attention control). Second, this proposed intervention is based on plausible pathophysiologic pathways. The collection of biomarkers will help in establishing the mechanisms between cognitive activity, physical activity, and cognitive decline among ICU survivors of delirium. Third, this approach of using a combined physical exercise and cognitive training is an innovative behavioral intervention that has the potential for additive effects on enhancing cognitive recovery following critical illness. Finally, the proposed use of computers and broadband Internet to deliver the physical exercise and cognitive training to older ICU survivors in their homes using trained coaches via videoconference reduces task difficulty and is part of the growing movement championed by the Centers for Disease Control called Healthy Aging 2.0 which encourages health service delivery via the Internet .
In summary, IMPROVE is the first randomized controlled trial to evaluate the efficacy of combined cognitive and physical training in improving the cognitive function among ICU survivors 50 or older who experienced delirium during their ICU stay. It will also provide valuable biomarker data to more deeply understand the pathophysiology of long-term cognitive impairment and dementia in survivors of ICU delirium, and potential therapeutic targets for future studies. Most importantly, this study will pave the way for a large effectiveness randomized controlled trial to test the combined intervention to delay time to a clinical diagnosis of Alzheimer disease and related dementias.
The study started recruiting October 1, 2017. The expected completion date is June 1, 2023.
We thank the subjects and their informal caregivers who are participating in the study.
SW is supported by NIA 2P30AG010133, NCATS UL1TR001108 (Project Development Team), and AZ160032. SK is supported by NHLBI 5T32HL091816-07. SG is supported by NIA 2P30AG010133, NIA 5R01AG045350, and NIA R01AG054205-02. AP is supported by CMS 1 L1 CMS331444-02-00, Indiana CTSI NCATS UL1TR001108, and NIA R01AG054205-02. FWU is supported by R01 AG045157, and P30AG10133. DC is supported by NHLBI R01 HL128494, AHRQ P30 HS024384-02, NIA R01AG045157. MB is supported by NIA R01 AG040220-05, AHRQ P30 HS024384-02, CMS 1 L1 CMS331444-02-00, NIA R01 AG030618-05A1 and NIA R01AG054205-02. BK is supported by NIA K23-AG043476, NHLBI R01HL131730, and NIA R01AG055391.
Availability of data and materials
No datasets are available at this time.
SW drafted the manuscript and provided intellectual input into the manuscript; JH participated in drafted the manuscript; SK provided intellectual input and revised the manuscript; SG provided intellectual input, designed the protocols, and revised the manuscript; AH participated in designing the protocols and revised the manuscript; SM participated in designing the protocols and revised the manuscript; LM participated in designing the protocols and revised the manuscript; AP provided intellectual input, designed the protocols, and revised the manuscript; FU provided intellectual input, participated in designing the study and protocols, and revised the manuscript; DC provided intellectual input, participated in designing the study and protocols, and revised the manuscript; MB provided intellectual input, participated in designing the study and protocols, and revised the manuscript; BK designed the study and the protocol as the principal investigator, provided intellectual input, and revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The protocol was approved by the Institutional Review Board at the Indiana University School of Medicine, #1608126693. The principal investigator and the research staff are responsible for conducting the informed consent process with all the study participants. Informed consent will be obtained from the subject or their legally authorized representative as appropriate. Changes to the study protocol and/or the informed consent will be sent to the Institutional Review Board as protocol amendments. All data will be de-identified prior to analysis; only the principal investigator and project manager will be able to access the code to identify the individual. The protocol was registered in ClinicalTrials.gov NCT03095417 on March 23, 2017 (https://clinicaltrials.gov/ct2/show/NCT03095417?term=NCT03095417&recrs=ab&rank=1) before starting the trial, and trial status will be updated accordingly.
Consent for publication
The authors declare that they have no competing interests. The funding agency had no role in the development of the study design, collection, analysis, interpretation of data, manuscript development, or the decision to submit the manuscript for publication.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 21.Pyoria O, Talvitie U, Nyrkko H, Kautiainen H, Pohjolainen T, Kasper V. The effect of two physiotherapy approaches on physical and cog- nitive functions and independent coping at home in stroke rehabilitation. A preliminary follow-up study. Disabil Rehabil. 2007;29:503–11.CrossRefPubMedGoogle Scholar
- 39.Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55(4):M221–31.CrossRefPubMedGoogle Scholar
- 40.Rikli R, Jones CJ. American College of Sports Medicine: Senior fitness test manual. Champaign: Human Kinetics; 2001.Google Scholar
- 47.Thompson PD, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007;115(17):2358–68.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.